A Phase II Study of AS1411 in Renal Cell Carcinoma

A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

Inclusion Criteria:

• Histologically or cytologically confirmed renal cell carcinoma containing predominant clear cell histology
• Failed or intolerant to 1 or more previous lines of treatments (which must include a Tyrosine Kinase Inhibitor)

Exclusion Criteria:

• Collecting duct histology
• A history of bleeding disorders or currently taking oral vitamin K antagonise medication
• Unstable brain metastases
• History of prior or concomitant malignancy (except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years)